Pablo Canales-Herrerias

Excited to share our new work in @SciImmunology! We describe targeting of gut-associated lymphoid tissue (GALT) as a novel mode of action of anti-α4β7 therapy in IBD. Co-led by @mat_uzz & A. Seki @MehandruLab @SinaiImmunol @MountSinaiGI @IcahnMountSinai🧵 science.org/doi/10.1126/sc…

📢 Looking for a #MasterThesis (TFM) opportunity? Join our lab at University of Barcelona! 🧬Project: Host–microbiota interaction in Crohn’s disease : from systems immunology to antibody engineering. 🔗Contact us to learn more! #translationalImmunology #Microbiome #antibodies

My lab @MBIsg and @NUSMedicine is recruiting a fully-funded postdoc to start in Jan 2026! Interested in cell and tissue mechanics, transcriptional regulation of tissue health, or AI/ML for disease mechanobiology? Come join us in Singapore! mechano-medicine-lab.com/positions

Excited to be starting my research group as a tenure track Presidential Young Professor at the Mechanobiology Institute @MBIsg, and the Dept of Physiology at @NUSingapore in the fall! More about our work on vascular mechanobiology: mechano-medicine-lab.com

Interested in pursuing a PhD thesis in our group in Demark? Interested in droplets, immune cells and cellular functions? Then definitely apply! phd.health.au.dk/application/op…

Please RT 🙏!📢My lab at @UniBarcelona is seeking a highly motivated postdoc to lead an exciting new public-private collaborative project (UB, CRG, CSIC, OrikineBio) aimed at testing a potentially game-changing therapy for IBD. If interested, please contact me at gmagri@ub.edu.

Intestinal germinal center B cell reduction in HIV-1 infection is linked to reduced IgA+ plasma cells and systemic inflammation @SciImmunology @francescacossa1 @saurabhmehandru science.org/doi/10.1126/sc…

Check this out from @francescacossa1 and @MehandruLab 🔥🔥 @SinaiImmunol @MountSinaiGI @SciImmunology 👇

@perlmannlab 🤞for Max Cooper and Jacques Miller

…. and only around 14 hours until the famous call from Stockholm. Here’s the phone I’ll use. If you expect the call, please stay alert @ around 9.30-10 CEST tomorrow!

🎉 Applications are open for the 2025 Pasteur-Paris University PhD Program (PPU)! Join a global community of researchers and contribute to groundbreaking biomedical discoveries. 📅 Deadline: October 27, 2024 🔗 Apply now: pasteur.fr/en/education/p… #research #institutpasteur

According to a Mount Sinai study, Vedolizumab, a mainstay drug for managing ulcerative colitis, appears to work by targeting gut-associated lymphoid tissue. Read more: mshs.co/3zacgc0 @DOMSinaiNYC @MountSinaiGI #IBD

We are looking for post-docs. Interested in early life human immunity and bioinformatics? We have a number of really interesting projects. Spread the word and please apply! @YalePediatrics @YaleIBIO

@JeanFredericCo1 🇫🇷🍾🥂

Very proud of my country today! 😁

Front-line drug for ulcerative colitis found to have additional mechanism of action that until now remained elusive medicalxpress.com/news/2024-07-f… via @medical_xpress

Front-line drug for ulcerative colitis found to have additional mechanism of action that until now remained elusive (Vdz) medicalxpress.com/news/2024-07-f… via @medical_xpress

Out now 🚨 in @AGA_Gastro is your latest update on selective IL-23p19 inhibition in IBD! Amongst other topics featuring discussion of pathogenesis, PD/PK, efficacy, safety, positioning, and more! Together with @JeanFredericCo1 @MehandruLab & @ryanungaro gastrojournal.org/article/S0016-…

@shailajaseethar Congrats @shailajaseethar!!

Preprint alert! The force-sensitive protein, FHL2, promotes atherosclerotic endothelial phenotypes (junction discontinuity, hypercontractility, and high tissue permeability) through actin-microtubule crosstalk!! Check out the whole story on bioRxiv: biorxiv.org/content/10.110…

@BourgonjeArno @EdelblumLab @MountSinaiGI @JeanFredericCo1 @ryanungaro @DrMikeDolinger @bruce_sands1 @IBDebrief @MSHS_IBDCenter @MehandruLab @a_livanos 🤣

@pabloimmune @EdelblumLab @MountSinaiGI @JeanFredericCo1 @ryanungaro @DrMikeDolinger @bruce_sands1 @IBDebrief @MSHS_IBDCenter @MehandruLab @a_livanos We will for always remember @pabloimmune's unparalleled vocals.

Every year, @JeanFredericCo1 hosts the GI Division #IBD Retreat to address challenging topics in #IBD. We're proud to keep the tradition going this year at IBD Retreat 2024! Register here to join: form.jotform.com/kalish39/IBDre…

Gut-associated lymphoid tissue may shape drugs' efficacy. .@pabloimmune & colleagues describe targeting of gut-associated lymphoid tissue as a novel mode of action of anti-α4β7 therapy in IBD via @SciImmunology: science.org/doi/10.1126/sc…